Markets:

Overview

News

Currencies

International

Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

39.66 +1.06 (+2.75%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

August 19, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Why Amylyx Pharmaceuticals Stock Skyrocketed Today ↗

August 18, 2026

GLP-1 drugs aren't just for weight loss.

Via The Motley Fool

Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock

August 18, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals (NASDAQ:AMLX) Misses on Q2 Bottom Line as LUCIDITY Readout Looms ↗

August 06, 2026

Via Chartmill

Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 Loss Slightly Wider Than Expected as All Eyes Turn to Q3 Avexitide Trial Data ↗

May 07, 2026

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 18, 2026

Gainers AIxCrypto Hldgs (NASDAQ:AIXC) stock increased by 132.0% to $1.65 during Tuesday's regular session. The market value of their outstanding shares is at $14.3 million. Amylyx Pharmaceuticals...

Via Benzinga

Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55% ↗

August 18, 2026

Amylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III LUCIDITY trial of avexitide met its primary endpoint, reducing the composite rate of clinically significant hypoglycemic events by 55% versus...

Via MarketBeat

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 18, 2026

Gainers Amylyx Pharmaceuticals (NASDAQ:AMLX) stock increased by 27.5% to $27.32 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.3 billion. bioAffinity...

Via Benzinga

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

August 18, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026

August 17, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx (AMLX) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

LUCIDITY data readout expected late August or early September.

Via The Motley Fool

Topics Earnings

Amylyx Pharmaceuticals Q2 Earnings Call Highlights ↗

August 06, 2026

Amylyx Pharmaceuticals (NASDAQ:AMLX) said its pivotal Phase III LUCIDITY trial of avexitide in post-bariatric hypoglycemia, or PBH, has completed final patient visits, with top-line data expected in...

Via MarketBeat

Topics Earnings

Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 06, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

August 03, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

June 23, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape ↗

June 10, 2026

Amylyx Pharmaceuticals (NASDAQ:AMLX) Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia,...

Via MarketBeat

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

June 08, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

What to Know About This Fund's $10 Million Bet on Gold Miners ↗

May 24, 2026

ASA Gold and Precious Metals Limited targets global mining equities, specializing in gold, silver, and other precious minerals investments.

Via The Motley Fool

Topics Economy

Amylyx Stock: Why the Full Pipeline Story Matters ↗

May 24, 2026

Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares

Via MarketBeat

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗

May 19, 2026

This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.

Via The Motley Fool

Topics Regulatory Compliance

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗

May 19, 2026

Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.

Via The Motley Fool

Topics Regulatory Compliance

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

May 15, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus ↗

May 14, 2026

Amylyx Pharmaceuticals (NASDAQ:AMLX) is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia, or PBH, with data from the LUCIDITY trial expected in the...

Via MarketBeat

Amylyx (AMLX) Q1 2026 Earnings Transcript ↗

May 08, 2026

Amylyx (AMLX) Q1 2026 Earnings Transcript

Via The Motley Fool

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

May 07, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

May 06, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

May 05, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

April 30, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

April 08, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

March 24, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.